Division of Cancer Biostatistics, University of Kentucky, Lexington, Kentucky.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky.
Cancer Med. 2018 Apr;7(4):1151-1159. doi: 10.1002/cam4.1404. Epub 2018 Mar 13.
Glioblastoma in children is an aggressive disease with no defined standard therapy. We evaluated hospital-based demographic and survival patterns obtained through the National Cancer Database to better characterize children with glioblastoma. Our study identified 1173 patients from 0 to 19 years of age between 1998 and 2011. Comparisons were made among demographics, clinical characteristics, treatment, and survival variables. Fifty-four percent of patients were over 10 years of age. Approximately 80% of patients underwent either partial or complete resection. Adjuvant therapy was used variably, and its use increased with patient age. Forty-eight percent of patients received the combination of surgery, radiation, and chemotherapy, and 4% did not receive any treatment. As expected, patients ≤5 years of age had better 5-year survival than those ages 6-10 (P = 0.01) or 11-19 years (P = 0.0077). Other factors associated with poor survival included black race and central tumor location. Better outcomes were associated with treatment that included surgery, radiotherapy, and chemotherapy compared to any other treatment combinations. Radiotherapy had no impact on survival in the 0 to 10-year-old age group, but was associated with improved survival for patients 11-19 years. We report an extensive demographic and survival analysis of pediatric glioblastoma. The observed differences likely reflect variances in tumor biology and likelihood of treatment receipt. Improved survival was associated with the use of surgery, radiotherapy, and chemotherapy. Radiation therapy was not associated with survival in patients younger than 10 years of age.
儿童胶质母细胞瘤是一种侵袭性疾病,目前尚无明确的标准治疗方法。我们评估了国家癌症数据库中基于医院的人口统计学和生存模式,以更好地描述儿童胶质母细胞瘤患者的特征。我们的研究在 1998 年至 2011 年期间确定了 1173 名 0 至 19 岁的患者。对人口统计学、临床特征、治疗和生存变量进行了比较。54%的患者年龄超过 10 岁。大约 80%的患者接受了部分或完全切除术。辅助治疗的使用各不相同,且随着患者年龄的增加而增加。48%的患者接受了手术、放疗和化疗的联合治疗,而 4%的患者未接受任何治疗。不出所料,≤5 岁的患者 5 年生存率高于 6-10 岁(P=0.01)或 11-19 岁(P=0.0077)的患者。与预后不良相关的其他因素包括黑种人和肿瘤位于中央。与任何其他治疗方案相比,包括手术、放疗和化疗在内的治疗方案与更好的生存结果相关。对于 0 至 10 岁的患者,放疗对生存没有影响,但与 11-19 岁患者的生存改善相关。我们报告了一项广泛的儿科胶质母细胞瘤的人口统计学和生存分析。观察到的差异可能反映了肿瘤生物学和治疗可能性的差异。生存的改善与手术、放疗和化疗的应用有关。对于年龄小于 10 岁的患者,放疗与生存无关。